IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

IDYA Stock Forecast

IDEAYA Biosciences stock forecast is as follows: an average price target of $46.58 (represents a 74.85% upside from IDYA’s last price of $26.64) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

IDYA Price Target

The average price target for IDEAYA Biosciences (IDYA) is $46.58 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $18.00. This represents a potential 74.85% upside from IDYA's last price of $26.64.

IDYA Analyst Ratings

Buy

According to 14 Wall Street analysts, IDEAYA Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for IDYA stock is 0 'Strong Buy' (0.00%), 12 'Buy' (85.71%), 2 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

IDEAYA Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Andrew Berens	Leerink Partners	$27.00	$29.58	-8.72%	1.35%
Oct 24, 2024	David Dai	UBS	$50.00	$29.50	69.49%	87.69%
Sep 25, 2024	Graig Suvannavejh	Mizuho Securities	$55.00	$31.37	75.33%	106.46%
Sep 23, 2024	Corinne Jenkins	Goldman Sachs	$48.00	$33.73	42.31%	80.18%
Sep 23, 2024	Ben Burnett	Stifel Nicolaus	$66.00	$33.73	95.67%	147.75%
Sep 23, 2024	Justin Zelin	BTIG	$62.00	$33.87	83.05%	132.73%
Sep 10, 2024	Ben Burnett	Stifel Nicolaus	$68.00	$36.97	83.93%	155.26%
Aug 27, 2024	Yigal Nochomovitz	Citigroup	$58.00	$39.80	45.73%	117.72%
Aug 07, 2024	Matthew Biegler	Oppenheimer	$53.00	$35.86	47.80%	98.95%
Jul 10, 2024	Gregory Renza	RBC Capital	$61.00	$37.33	63.41%	128.98%

Row per page

Go to

The latest IDEAYA Biosciences stock forecast, released on Nov 05, 2024 by Andrew Berens from Leerink Partners, set a price target of $27.00, which represents a -8.72% decrease from the stock price at the time of the forecast ($29.58), and a 1.35% increase from IDYA last price ($26.64).

IDEAYA Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	2	8	12
Avg Price Target	$38.50	$54.25	$55.08
Last Closing Price	$26.64	$26.64	$26.64
Upside/Downside	44.52%	103.64%	106.76%

In the current month, the average price target of IDEAYA Biosciences stock is $38.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 44.52% increase as opposed to IDEAYA Biosciences's last price of $26.64. This month's average price target is down -29.03% compared to last quarter, and down -30.10% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	Leerink Partners	-	Market Perform	Downgrade
Oct 24, 2024	UBS	-	Buy	Initialise
Oct 15, 2024	Cantor Fitzgerald	-	Overweight	Initialise
Sep 24, 2024	RBC Capital	Outperform	Outperform	Hold
Sep 23, 2024	Citigroup	Buy	Buy	Hold
Sep 23, 2024	Goldman Sachs	Buy	Buy	Hold
Sep 23, 2024	BTIG	Buy	Buy	Hold
Sep 23, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 27, 2024	Citigroup	Buy	Buy	Hold
Aug 07, 2024	Oppenheimer	Outperform	Outperform	Hold

Row per page

Go to

IDEAYA Biosciences's last stock rating was published by Leerink Partners on Nov 05, 2024. The company Downgrade its IDYA rating from "null" to "Market Perform".

IDEAYA Biosciences Financial Forecast

IDEAYA Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$8.04M	$3.54M	$7.88M	$4.02M	$29.70M	$5.85M	$11.36M	$-38.02M	$24.98M	$8.76M	$7.25M	$10.57M	$8.97M	-
Avg Forecast	$13.02M	$9.39M	$7.40M	$3.96M	$3.45M	$2.76M	$2.74M	$3.45M	$6.06M	$4.27M	$4.46M	$5.43M	$8.84M	$8.38M	$4.89M	$6.14M	$7.00M	$6.64M	$7.69M	$6.71M	$8.98M	$8.55M	$14.24M	$7.48M	$7.92M	$70.56M	$100.00M
High Forecast	$14.81M	$10.68M	$8.42M	$4.51M	$3.93M	$3.14M	$3.11M	$4.32M	$6.89M	$4.31M	$4.46M	$5.43M	$17.39M	$9.53M	$5.57M	$6.99M	$7.96M	$6.64M	$7.69M	$6.71M	$8.98M	$8.55M	$14.24M	$7.48M	$7.92M	$70.56M	$100.00M
Low Forecast	$11.22M	$8.09M	$6.37M	$3.41M	$2.97M	$2.37M	$2.36M	$2.57M	$5.22M	$4.24M	$4.46M	$5.43M	$3.48M	$7.22M	$4.21M	$5.29M	$6.03M	$6.64M	$7.69M	$6.71M	$8.98M	$8.55M	$14.24M	$7.48M	$7.92M	$70.56M	$100.00M
# Analysts	4	4	4	4	3	3	3	5	8	4	3	3	6	10	9	9	8	8	8	8	9	9	9	9	9	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.96%	0.72%	1.28%	0.57%	4.47%	0.76%	1.69%	-4.23%	2.92%	0.61%	0.97%	1.33%	0.13%	-

IDEAYA Biosciences's average Quarter revenue forecast for Dec 23 based on 6 analysts is $8.84M, with a low forecast of $3.48M, and a high forecast of $17.39M. IDYA's average Quarter revenue forecast represents a 10.03% increase compared to the company's last Quarter revenue of $8.04M (Sep 23).

IDEAYA Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	4	4	4	4	3	3	3	5	8	4	3	3	6	10	9	9	8	8	8	8	9	9	9	9	9	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-33.53M	$-32.71M	$-26.28M	$-26.44M	$1.58M	$-21.30M	$-11.66M	$1.76M	$-29.92M	$-10.50M	$-8.64M	$355.87K	$-4.58M	$-12.05M
Avg Forecast	$-7.81M	$-5.63M	$-4.44M	$-2.38M	$-2.07M	$-1.65M	$-1.64M	$-2.07M	$-3.63M	$-2.56M	$-2.67M	$-3.26M	$-5.31M	$-5.03M	$-2.93M	$-3.69M	$-4.20M	$-3.99M	$-4.62M	$-17.32M	$-5.39M	$-5.13M	$-8.55M	$-8.32M	$-4.75M	$-42.33M	$-60.00M
High Forecast	$-6.73M	$-4.85M	$-3.82M	$-2.05M	$-1.78M	$-1.42M	$-1.42M	$-1.54M	$-3.13M	$-2.55M	$-2.67M	$-3.26M	$-2.09M	$-4.33M	$-2.53M	$-3.18M	$-3.62M	$-3.99M	$-4.62M	$-13.85M	$-5.39M	$-5.13M	$-8.55M	$-6.66M	$-4.75M	$-42.33M	$-60.00M
Low Forecast	$-8.89M	$-6.41M	$-5.05M	$-2.71M	$-2.36M	$-1.88M	$-1.87M	$-2.59M	$-4.13M	$-2.58M	$-2.67M	$-3.26M	$-10.44M	$-5.72M	$-3.34M	$-4.19M	$-4.78M	$-3.99M	$-4.62M	$-20.78M	$-5.39M	$-5.13M	$-8.55M	$-9.98M	$-4.75M	$-42.33M	$-60.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	6.67%	11.14%	7.13%	6.30%	-0.40%	4.61%	0.67%	-0.33%	5.83%	1.23%	1.04%	-0.07%	0.11%	0.20%

8 analysts predict IDYA's average Quarter EBITDA for Dec 22 to be $-4.20M, with a high of $-3.62M and a low of $-4.78M. This is -364.98% lower than IDEAYA Biosciences's previous annual EBITDA (Sep 22) of $1.58M.

IDEAYA Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	4	4	4	4	3	3	3	5	8	4	3	3	6	10	9	9	8	8	8	8	9	9	9	9	9	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-27.44M	$-27.93M	$-20.04M	$-21.96M	$2.57M	$-21.61M	$-17.99M	$21.88M	$-31.55M	$-10.95M	$-9.02M	$-5.13K	$-4.93M	$-12.39M
Avg Forecast	$-74.36M	$-74.10M	$-72.61M	$-72.12M	$-64.02M	$-61.47M	$-57.96M	$-54.54M	$-53.64M	$-55.82M	$-46.16M	$-44.40M	$-40.31M	$-42.16M	$-47.56M	$-46.66M	$-47.83M	$-47.26M	$-39.38M	$-18.07M	$-24.26M	$-23.59M	$-5.46M	$-8.69M	$-23.34M	$228.24M	$142.45M
High Forecast	$-60.97M	$-60.76M	$-59.53M	$-59.14M	$-52.49M	$-50.41M	$-47.52M	$-50.12M	$-49.64M	$-45.77M	$-37.85M	$-36.41M	$-27.97M	$-21.51M	$-38.99M	$-38.26M	$-39.22M	$-47.26M	$-39.38M	$-14.46M	$-24.26M	$-23.59M	$-5.46M	$-6.95M	$-23.34M	$228.24M	$142.45M
Low Forecast	$-87.69M	$-87.38M	$-85.62M	$-85.05M	$-75.49M	$-72.49M	$-68.34M	$-61.91M	$-57.65M	$-65.82M	$-54.44M	$-52.36M	$-54.29M	$-66.25M	$-56.08M	$-55.02M	$-56.40M	$-47.26M	$-39.38M	$-21.68M	$-24.26M	$-23.59M	$-5.46M	$-10.42M	$-23.34M	$228.24M	$142.45M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.65%	0.59%	0.43%	0.46%	-0.05%	0.55%	1.00%	-0.90%	1.34%	2.01%	1.04%	0.00%	-0.02%	-0.09%

IDEAYA Biosciences's average Quarter net income forecast for Dec 22 is $-47.83M, with a range of $-56.40M to $-39.22M. IDYA's average Quarter net income forecast represents a -1961.20% decrease compared to the company's last Quarter net income of $2.57M (Sep 22).

IDEAYA Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	4	4	4	4	3	3	3	5	8	4	3	3	6	10	9	9	8	8	8	8	9	9	9	9	9	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.86M	$7.08M	$6.30M	$5.75M	$6.67M	$5.55M	$5.92M	-	$14.83M	$4.83M	$4.82M	$3.80M	$3.94M	$3.99M
Avg Forecast	$10.87M	$7.84M	$6.18M	$3.31M	$2.88M	$2.30M	$2.29M	$2.88M	$5.06M	$3.57M	$3.72M	$4.54M	$7.38M	$7.00M	$4.08M	$5.13M	$5.84M	$5.55M	$6.42M	$6.65M	$7.50M	$7.14M	$11.89M	$4.64M	$6.62M	$58.91M	$83.49M
High Forecast	$12.37M	$8.92M	$7.03M	$3.76M	$3.28M	$2.62M	$2.60M	$3.61M	$5.75M	$3.59M	$3.72M	$4.54M	$14.52M	$7.96M	$4.65M	$5.84M	$6.65M	$5.55M	$6.42M	$7.97M	$7.50M	$7.14M	$11.89M	$5.57M	$6.62M	$58.91M	$83.49M
Low Forecast	$9.36M	$6.75M	$5.32M	$2.85M	$2.48M	$1.98M	$1.97M	$2.15M	$4.36M	$3.54M	$3.72M	$4.54M	$2.90M	$6.03M	$3.52M	$4.42M	$5.03M	$5.55M	$6.42M	$5.32M	$7.50M	$7.14M	$11.89M	$3.71M	$6.62M	$58.91M	$83.49M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.12%	1.73%	1.23%	0.98%	1.20%	0.86%	0.89%	-	2.08%	0.41%	1.04%	0.57%	0.07%	0.05%

IDEAYA Biosciences's average Quarter SG&A projection for Dec 23 is $7.38M, based on 6 Wall Street analysts, with a range of $2.90M to $14.52M. The forecast indicates a -6.09% fall compared to IDYA last annual SG&A of $7.86M (Sep 23).

IDEAYA Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	4	4	4	4	3	3	3	5	8	4	3	3	6	10	9	9	8	8	8	8	9	9	9	9	9	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.46	$-0.00	$-0.41	$-0.46	$0.06	$-0.56	$-0.47	$0.57	$-0.31	$-0.33	$-0.28	$-0.00	$-0.17	$-0.59
Avg Forecast	$-0.86	$-0.86	$-0.84	$-0.84	$-0.74	$-0.71	$-0.67	$-0.63	$-0.62	$-0.65	$-0.54	$-0.52	$-0.47	$-0.49	$-0.55	$-0.54	$-0.55	$-0.61	$-0.51	$-0.41	$-0.31	$-0.30	$-0.07	$-0.30	$-0.30	$2.93	$1.83
High Forecast	$-0.71	$-0.70	$-0.69	$-0.69	$-0.61	$-0.58	$-0.55	$-0.58	$-0.58	$-0.53	$-0.44	$-0.42	$-0.32	$-0.25	$-0.45	$-0.44	$-0.46	$-0.61	$-0.51	$-0.41	$-0.31	$-0.30	$-0.07	$-0.30	$-0.30	$2.93	$1.83
Low Forecast	$-1.02	$-1.01	$-0.99	$-0.99	$-0.88	$-0.84	$-0.79	$-0.72	$-0.67	$-0.76	$-0.63	$-0.61	$-0.63	$-0.77	$-0.65	$-0.64	$-0.65	$-0.61	$-0.51	$-0.41	$-0.31	$-0.30	$-0.07	$-0.30	$-0.30	$2.93	$1.83
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	0.00%	0.76%	0.83%	-0.11%	1.11%	1.14%	-1.83%	1.02%	4.71%	0.94%	0.00%	-0.06%	-0.32%

According to 8 Wall Street analysts, IDEAYA Biosciences's projected average Quarter EPS for Dec 22 is $-0.55, with a low estimate of $-0.65 and a high estimate of $-0.46. This represents a -969.87% decrease compared to IDYA previous annual EPS of $0.06 (Sep 22).

IDEAYA Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.87	$33.86	1710.70%	Buy
XFOR	X4 Pharmaceuticals	$0.40	$3.67	817.50%	Buy
INZY	Inozyme Pharma	$3.13	$14.67	368.69%	Buy
ABOS	Acumen Pharmaceuticals	$2.40	$7.00	191.67%	Buy
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
ANAB	AnaptysBio	$19.00	$52.00	173.68%	Buy
TERN	Terns Pharmaceuticals	$6.17	$14.25	130.96%	Buy
SNDX	Syndax Pharmaceuticals	$15.83	$34.30	116.68%	Buy
SWTX	SpringWorks Therapeutics	$36.45	$67.33	84.72%	Buy
KROS	Keros Therapeutics	$56.62	$102.60	81.21%	Buy
IDYA	IDEAYA Biosciences	$26.64	$46.58	74.85%	Buy
MLTX	MoonLake Immunotherapeutics	$48.83	$79.33	62.46%	Buy
MGTX	MeiraGTx	$6.48	$9.00	38.89%	Buy
RNA	Avidity Biosciences	$42.18	$54.50	29.21%	Buy
PTGX	Protagonist Therapeutics	$41.11	$50.00	21.62%	Buy
AMLX	Amylyx Pharmaceuticals	$4.76	$5.33	11.97%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$55.13	$60.63	9.98%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
VRNA	Verona Pharma	$35.66	$33.86	-5.05%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

IDYA Forecast FAQ

Is IDEAYA Biosciences a good buy?

Yes, according to 14 Wall Street analysts, IDEAYA Biosciences (IDYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 85.71% of IDYA's total ratings.

What is IDYA's price target?

IDEAYA Biosciences (IDYA) average price target is $46.58 with a range of $18 to $66, implying a 74.85% from its last price of $26.64. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will IDEAYA Biosciences stock go up soon?

According to Wall Street analysts' prediction for IDYA stock, the company can go up by 74.85% (from the last price of $26.64 to the average price target of $46.58), up by 147.75% based on the highest stock price target, and down by -32.43% based on the lowest stock price target.

Can IDEAYA Biosciences stock reach $40?

IDYA's average twelve months analyst stock price target of $46.58 supports the claim that IDEAYA Biosciences can reach $40 in the near future.

What is IDEAYA Biosciences's current price target trend?

2 Wall Street analysts forecast a $38.5 price target for IDEAYA Biosciences (IDYA) this month, up 44.52% from its last price of $26.64. Compared to the last 3 and 12 months, the average price target increased by 103.64% and increased by 106.76%, respectively.

What are IDEAYA Biosciences's analysts' financial forecasts?

IDEAYA Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $12.39M (high $14.5M, low $10.28M), average EBITDA is $-7.436M (high $-6.167M, low $-8.699M), average net income is $-238M (high $-201M, low $-278M), average SG&A $10.35M (high $12.1M, low $8.58M), and average EPS is $-2.761 (high $-2.327, low $-3.228). IDYA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $33.77M (high $38.42M, low $29.09M), average EBITDA is $-20.26M (high $-17.454M, low $-23.053M), average net income is $-293M (high $-240M, low $-346M), average SG&A $28.19M (high $32.08M, low $24.29M), and average EPS is $-3.402 (high $-2.789, low $-4.011).

Did the IDYA's actual financial results beat the analysts' financial forecasts?

Based on IDEAYA Biosciences's last annual report (Dec 2022), the company's revenue was $50.93M, beating the average analysts forecast of $28.04M by 81.61%. Apple's EBITDA was $-62.502M, beating the average prediction of $-30.117M by 107.53%. The company's net income was $-54.808M, missing the average estimation of $-153M by -64.07%. Apple's SG&A was $23.9M, missing the average forecast of $24.46M by -2.29%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-2.077 by -36.46%. In terms of the last quarterly report (Sep 2023), IDEAYA Biosciences's revenue was $8.04M, missing the average analysts' forecast of $8.38M by -4.08%. The company's EBITDA was $-33.526M, beating the average prediction of $-5.028M by 566.82%. IDEAYA Biosciences's net income was $-27.44M, missing the average estimation of $-42.158M by -34.91%. The company's SG&A was $7.86M, beating the average forecast of $7M by 12.39%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.489 by -5.96%